Everolimus After Alpelisib for Advanced Breast Cancer
Part of Cancer clinical trials.
This trial tests a drug called everolimus in women with hormone receptor-positive metastatic breast cancer who have already tried alpelisib (a PI3K inhibitor) combined with hormone therapy. The goal is to see if this next treatment can help control cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have hormone receptor-positive metastatic breast cancer (cancer that has spread beyond the breast)
- Your cancer has a specific genetic change called PI3K mutation
- You have already received CDK 4/6 inhibitors (like palbociclib or ribociclib) plus hormone therapy
- You have already received alpelisib (a PI3K inhibitor) combined with hormone therapy
- You are willing to try a new drug combination as your next treatment step
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding everolimus to standard first-line hormone (endocrine) therapy can better control a certain type of advanced breast cancer. It is designed for people whose tumor matches a specific “SNF1 subtype.”
This trial tests a drug called everolimus for people with advanced colorectal cancer that has a specific change in a gene called CDK12. It aims to see if this drug can slow down the cancer when other treatments have stopped working.
This trial tests a combination of two drugs, chidamide and everolimus, for people with advanced HR+/HER2- breast cancer. It aims to see if the combination works for tumors with or without a PIK3CA gene mutation. You may be able to join if you've had previous treatment with CDK4/6 inhibitors and up to two prior chemotherapies.
This trial tests a new combination of two oral targeted therapy pills (elacestrant and everolimus) for people with a specific type of advanced breast cancer. It is for those whose cancer has an ESR1 mutation and has stopped responding to CDK4/6 inhibitors and hormone therapy.
This trial studies a drug called everolimus given after liver cancer surgery to see if it helps prevent the cancer from returning. Everolimus is a pill that may help stop cancer cell growth.
This Phase 2 study tests a genetically guided treatment plan for ER-positive breast cancer that has progressed after CDK4/6 therapy. It may help by matching treatment to tumor genetic changes.
Hear when a new Hormone-receptor-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.